Provided by Tiger Fintech (Singapore) Pte. Ltd.

Capricor Therapeutics

11.25
+1.6116.70%
Post-market: 11.350.1000+0.89%19:58 EDT
Volume:1.51M
Turnover:16.45M
Market Cap:513.86M
PE:-9.79
High:11.32
Open:10.20
Low:10.20
Close:9.64
Loading ...

Capricor Therapeutics Shares Gain 10.6% Premarket After FDA Grants Priority Review to Co's Therapy for a Muscle-Wasting Related Heart Condition

THOMSON REUTERS
·
04 Mar

Capricor Therapeutics Receives FDA's Acceptance for Review of BLA for Duchenne Muscular Dystrophy Treatment

MT Newswires Live
·
04 Mar

Analysts Conflicted on These Healthcare Names: Pliant Therapeutics (PLRX) and Capricor Therapeutics (CAPR)

TIPRANKS
·
04 Mar

Capricor Therapeutics' Cell Therapy for Muscular Dystrophy Patients to Get FDA Priority Review

Dow Jones
·
04 Mar

Capricor Therapeutics Announces FDA Acceptance and Priority Review of Its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

THOMSON REUTERS
·
04 Mar

Capricor Therapeutics Inc - FDA Assigns Pdufa Target Action Date of August 31, 2025

THOMSON REUTERS
·
04 Mar

Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

GlobeNewswire
·
04 Mar

Capricor Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
04 Mar

Capricor Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
28 Feb

Capricor Therapeutics options imply 31.0% move in share price post-earnings

TIPRANKS
·
28 Feb

Capricor Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
24 Feb

High Growth Tech Stocks In The United States To Watch

Simply Wall St.
·
18 Feb

Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?

Zacks
·
05 Feb

Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 54% CAGR over 5 years, surging 12% in the last week alone

Simply Wall St.
·
22 Jan

Capricor Therapeutics: Promising Advances in Duchenne Cardiomyopathy Treatment Drive Buy Rating

TIPRANKS
·
04 Jan

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Zacks
·
03 Jan

Capricor Therapeutics Price Target Maintained With a $77.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Jan

Capricor Therapeutics: Strategic Advances and Regulatory Progress Drive Buy Rating

TIPRANKS
·
02 Jan

Capricor Completes BLA Submission for Deramiocel to Treat DMD Cardiomyopathy

MT Newswires Live
·
02 Jan

Capricor Therapeutics completes submission of BLA to FDA for deramiocel

TIPRANKS
·
02 Jan